【drug-news】诺华的Onbrez对慢性阻塞性肺病的疗效要优于辉瑞的Spiriva
发布于 2010-11-03 · 浏览 1815 · IP 北京北京
这个帖子发布于 14 年零 212 天前，其中的信息可能已发生改变或有所发展。
Novartis's Onbrez better than Pfizer drug in COPD
Study found Onbrez reduced breathlessness more effectively
ZURICH, Nov 3 (Reuters) - Swiss drugmaker Novartis AG's (NOVN.VX) lung drug Onbrez reduced breathlessness more effectively than Pfizer's (PFE.N) Spiriva in patients with a deadly lung disease, a late-stage trial found.
Novartis also said on Wednesday the trial found chronic obstructive pulmonary disease (COPD) patients on Onbrez used rescue medication less compared with those taking Spiriva, known generically as tiotropium.
It also said Onbrez was as effective as Spiriva in improving lung function.
The news, which underscored the strength of Novartis's pipeline, came after a recent raft of upbeat data, including U.S. approval for multiple sclerosis drug Gilenya. This has boosted sentiment in Novartis and the group now trades at a premium to cross-town rival Roche (ROG.VX).
COPD is a progressive, life-threatening respiratory disease commonly caused by cigarette smoke and other harmful fumes and particles, resulting in inflammation and narrowing of airways.
It affects 210 million people worldwide and is projected to be the third leading cause of death by 2020, Novartis said.
Onbrez Breezhaler won European Union approval in COPD last year, boosting Novartis's ambitions in respiratory medicine, a field currently dominated by AstraZeneca (AZN.L), GlaxoSmithKline (GSK.L) and Pfizer.
Until recently, Novartis was not on the radar as a major force in lung drugs which are typically difficult to make because of the inhaler devices needed.
The field is now becoming increasingly important to Novartis as it develops new drugs and cheap generic versions of older products such as Glaxo's Advair.
Novartis recently hit a setback, however, when its experimental once-daily inhaled product QMF149, being developed for asthma and COPD hit a delay.
http://www.reuters.com/article/idCNLDE6A20B020101103?rpc=44
Study found Onbrez reduced breathlessness more effectively
ZURICH, Nov 3 (Reuters) - Swiss drugmaker Novartis AG's (NOVN.VX) lung drug Onbrez reduced breathlessness more effectively than Pfizer's (PFE.N) Spiriva in patients with a deadly lung disease, a late-stage trial found.
Novartis also said on Wednesday the trial found chronic obstructive pulmonary disease (COPD) patients on Onbrez used rescue medication less compared with those taking Spiriva, known generically as tiotropium.
It also said Onbrez was as effective as Spiriva in improving lung function.
The news, which underscored the strength of Novartis's pipeline, came after a recent raft of upbeat data, including U.S. approval for multiple sclerosis drug Gilenya. This has boosted sentiment in Novartis and the group now trades at a premium to cross-town rival Roche (ROG.VX).
COPD is a progressive, life-threatening respiratory disease commonly caused by cigarette smoke and other harmful fumes and particles, resulting in inflammation and narrowing of airways.
It affects 210 million people worldwide and is projected to be the third leading cause of death by 2020, Novartis said.
Onbrez Breezhaler won European Union approval in COPD last year, boosting Novartis's ambitions in respiratory medicine, a field currently dominated by AstraZeneca (AZN.L), GlaxoSmithKline (GSK.L) and Pfizer.
Until recently, Novartis was not on the radar as a major force in lung drugs which are typically difficult to make because of the inhaler devices needed.
The field is now becoming increasingly important to Novartis as it develops new drugs and cheap generic versions of older products such as Glaxo's Advair.
Novartis recently hit a setback, however, when its experimental once-daily inhaled product QMF149, being developed for asthma and COPD hit a delay.
http://www.reuters.com/article/idCNLDE6A20B020101103?rpc=44
最后编辑于 2022-10-09 · 浏览 1815
4 收藏点赞
